Inflammatory Myofibroblastic Tumor
Symptoms, Doctors, Treatments, Advances & More

Inflammatory Myofibroblastic Tumor Overview

Save information for later
Sign Up

Learn About Inflammatory Myofibroblastic Tumor

What is the definition of Inflammatory Myofibroblastic Tumor?
An Inflammatory myofibroblastic tumor (IMT) is an uncommon, usually benign (non-cancerous) tumor made up of cells called myofibroblastic spindle cells. It usually develops in children or young adults, but can affect people of any age. An IMT can occur in almost any part of the body but is most commonly found in the lung, orbit (eye socket), peritoneum (lining of the abdominal cavity and internal organs), and mesentery. Signs and symptoms vary depending on the site of the tumor. Some people with an IMT are asymptomatic, while others may have nonspecific respiratory symptoms, fever, or pain. IMTs may recur, and become locally invasive and/or spread (metastasize) to other parts of the body. However, malignant (cancerous) IMTs are rare. The underlying cause of IMTs is poorly understood. Some cases have been linked to translocations involving the ALK gene.
What are the alternative names for Inflammatory Myofibroblastic Tumor?
  • Inflammatory myofibroblastic tumor
  • Inflammatory fibrosarcoma
Who are the top Inflammatory Myofibroblastic Tumor Local Doctors?
Elite in Inflammatory Myofibroblastic Tumor
Elite in Inflammatory Myofibroblastic Tumor
Referral may be required
Leuven, VLG, BE 

Patrick Schoffski practices practicing medicine in Leuven, Belgium. Mr. Schoffski is rated as an Elite expert by MediFind in the treatment of Inflammatory Myofibroblastic Tumor. He is also highly rated in 21 other conditions, according to our data. His clinical expertise encompasses Gastrointestinal Stromal Tumor, Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Tissue Biopsy.

Elite in Inflammatory Myofibroblastic Tumor
Elite in Inflammatory Myofibroblastic Tumor
Referral may be required
Leuven, VLG, BE 

Raf Sciot practices practicing medicine in Leuven, Belgium. Sciot is rated as an Elite expert by MediFind in the treatment of Inflammatory Myofibroblastic Tumor. They are also highly rated in 22 other conditions, according to our data. Their clinical expertise encompasses Inflammatory Myofibroblastic Tumor, Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Thrombectomy, and Fasciotomy.

 
 
 
 
Learn about our expert tiers
Learn More
Advanced in Inflammatory Myofibroblastic Tumor
Dr. Frank Song
Hematology | Oncology
Advanced in Inflammatory Myofibroblastic Tumor
Dr. Frank Song
Hematology | Oncology
Referral may be required

Reading Hospital Hematology Oncology

824 Main St, Ste 101, 
Phoenixville, PA 
610-983-1800
Languages Spoken:
English, Mandarin
See accepted insurances
Offers Telehealth

Frank Song is a Hematologist and an Oncologist practicing medicine in Phoenixville, Pennsylvania. Dr. Song is rated as an Advanced provider by MediFind in the treatment of Inflammatory Myofibroblastic Tumor. He is also highly rated in 73 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Stomach Cancer, Lung Adenocarcinoma, Endoscopy, and Sacral Nerve Stimulation. Dr. Song is board certified in American Board Of Internal Medicine.

View All Doctors
What are the latest Inflammatory Myofibroblastic Tumor Clinical Trials?
A Phase I/II Study of Brigatinib in Pediatric and Young Adult Patients With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
A Phase I/II Study of Brigatinib in Pediatric and Young Adult Patients With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
Who is this study for: Pediatric and young adult patients with ALK+ anaplastic large cell lymphoma, inflammatory myofibroblastic tumors or other solid tumors
Enrollment Status: Recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: Brigatinib
Study Phase: Phase 1/Phase 2

Summary: This is an open-label, phase I-II dose-escalation and expansion study designed to define the recommended dose of brigatinib as monotherapy in pediatric and young adult patients with ALK+ ALCL, IMT or other solid tumors and to evaluate the pharmacokinetics (PK), (long-term) safety, and efficacy of brigatinib in these children.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
Who is this study for: Patients with Solid Tumors
Enrollment Status: Recruiting
Publish Date: November 19, 2025
Intervention Type: Drug
Study Drug: Oral Repotrectinib (TPX-0005)
Study Phase: Phase 1/Phase 2

Summary: Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center